Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Conclusion: The roxadustat dose required to maintain target hemoglobin in NDD patients in Japan with anemia of CKD relative to DA dose may not be impacted by low-grade inflammation. Roxadustat may be beneficial for ESA-hyporesponsive NDD CKD patients.Am J Nephrol
Source: American Journal of Nephrology - Category: Neurology Source Type: research
More News: Anemia | Aranesp | Chronic Kidney Disease | Iron | Japan Health | Neurology | Study | Urology & Nephrology